← Oncology Approval Tracker

FDA DECISION ·

Imfinzi + gemcitabine and cisplatin

durvalumab plus gemcitabine and cisplatin · AstraZeneca

FDA approvalNew or expanded indicationBiliary tract cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with locally advanced or metastatic biliary tract cancer treated with durvalumab in combination with gemcitabine and cisplatin.

LAMPGEN ANALYSIS

Why it matters

The action adds a PD-L1 inhibitor to a platinum-gemcitabine backbone for advanced biliary tract cancers.

What research teams should watch

Capture the biliary primary site and align chemotherapy cycle dates, maintenance transition and immune toxicity follow-up.

PRIMARY RECORDS

Sources